FDA approves leukemia drug from Roche

November 1, 2013

The Food and Drug Administration has approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.

The agency cleared Gazyva to fight in combination with in who haven't previously been treated for the disease.

Gazyva works by killing cancer cells and encouraging the immune system to fight them.

The FDA approved the drug based on a study showing Gazyva plus chemotherapy was superior to chemotherapy alone at slowing the progress of the disease. Patients treated with Gazyva had median survival of 23 months before death, relapse or worsening of their disease. That compares with 11.1 months for the chemotherapy patients.

Gazyva will be marketed by Roche's Genentech unit, based in South San Francisco.

Explore further: New drug approved for lack of certain white blood cells

Related Stories

New drug approved for lack of certain white blood cells

August 30, 2012

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

New drug treatment for form of lethal cancer is approved

July 6, 2013

A new drug has been approved to battle mantle cell lymphoma, an aggressive cancer often fatal because of its resistance to treatment, after a study led by a Hackensack University Medical Center physician showed it can stop ...

FDA: Roche drug works in early-stage breast cancer

September 10, 2013

The U.S. Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.